GFC Life Science KRX:388610KOSDAQ
지에프씨생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked0since Sep 11
In Q2 2026, GFC Life Science reported revenue of ₩5.5bn, up 21.7% year on year, and operating profit of ₩581m. GFC Life Science (지에프씨생명과학) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Insider buying Major holder adding Screener
GFC Life Science quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩5.5bn | +21.7% | ₩581m | ₩417m |
| Q1 2026 | ₩5.0bn | +12.2% | ₩464m | ₩477m |
| Q4 2025 derived | ₩4.6bn | +4.2% | ₩80m | ₩469m |
| Q3 2025 | ₩4.2bn | +10.6% | −₩284m | −₩288m |
| Q2 2025 | ₩4.5bn | -4.1% | ₩193m | ₩76m |
| Q1 2025 | ₩4.5bn | – | ₩398m | ₩298m |
| Q4 2024 derived | ₩4.4bn | – | ₩768m | ₩3.6bn |
| Q3 2024 | ₩3.8bn | – | −₩135m | −₩454m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
GFC Life Science top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest GFC Life Science news Korean headlines
No articles yet.